1. Home
  2. CGEN vs KNDI Comparison

CGEN vs KNDI Comparison

Compare CGEN & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • KNDI
  • Stock Information
  • Founded
  • CGEN 1993
  • KNDI 2002
  • Country
  • CGEN Israel
  • KNDI China
  • Employees
  • CGEN N/A
  • KNDI N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • KNDI Auto Manufacturing
  • Sector
  • CGEN Health Care
  • KNDI Consumer Discretionary
  • Exchange
  • CGEN Nasdaq
  • KNDI Nasdaq
  • Market Cap
  • CGEN 117.8M
  • KNDI 103.2M
  • IPO Year
  • CGEN 2000
  • KNDI N/A
  • Fundamental
  • Price
  • CGEN $1.47
  • KNDI $1.12
  • Analyst Decision
  • CGEN Strong Buy
  • KNDI
  • Analyst Count
  • CGEN 1
  • KNDI 0
  • Target Price
  • CGEN $4.00
  • KNDI N/A
  • AVG Volume (30 Days)
  • CGEN 216.5K
  • KNDI 87.4K
  • Earning Date
  • CGEN 05-19-2025
  • KNDI 06-10-2025
  • Dividend Yield
  • CGEN N/A
  • KNDI N/A
  • EPS Growth
  • CGEN N/A
  • KNDI N/A
  • EPS
  • CGEN N/A
  • KNDI N/A
  • Revenue
  • CGEN $27,589,000.00
  • KNDI $127,569,613.00
  • Revenue This Year
  • CGEN $11.81
  • KNDI N/A
  • Revenue Next Year
  • CGEN $28.37
  • KNDI N/A
  • P/E Ratio
  • CGEN N/A
  • KNDI N/A
  • Revenue Growth
  • CGEN N/A
  • KNDI 3.21
  • 52 Week Low
  • CGEN $1.13
  • KNDI $0.89
  • 52 Week High
  • CGEN $2.66
  • KNDI $2.25
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 53.98
  • KNDI 41.81
  • Support Level
  • CGEN $1.38
  • KNDI $1.01
  • Resistance Level
  • CGEN $1.56
  • KNDI $1.18
  • Average True Range (ATR)
  • CGEN 0.08
  • KNDI 0.08
  • MACD
  • CGEN 0.02
  • KNDI -0.00
  • Stochastic Oscillator
  • CGEN 68.97
  • KNDI 32.35

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

Share on Social Networks: